search
Back to results

Collaborative Specialty Care for Gulf War Illness

Primary Purpose

Gulf War Illness

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Collaborative Specialty Care
e-consultation
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gulf War Illness focused on measuring Veteran, Gulf War Illness, implementation, Chronic Pain, health coaching, problem-solving

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • deployed to Operation Desert Shield/Storm
  • meets Kansas City (Steele) definition of GWI (which excludes conditions that may account for GWI)
  • rates their activity limitations from pain at least 3 on a 0 to 10 point scale
  • has a VA primary care provider

Exclusion Criteria:

  • suicidal intent
  • previous evaluation at the WRIISC or participated in our clinical trial for GWVs with GWI

Sites / Locations

  • East Orange Campus of the VA New Jersey Health Care System, East Orange, NJRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

collaborative specialty care

e-consultation

Arm Description

In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.

In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.

Outcomes

Primary Outcome Measures

Roland Morris Disability Scale
Pain disability will be assessed with the RMDS a 24 item scale of disability from pain. The RMDS is a core outcome measure for patients with chronic pain. A change of 2-3 points is considered clinically significant. Pain is present in 99% of GWVs with GWI and previous collaborative care trials in the VA have used this measure. Scores range from 0-24 with higher scores = greater disability.
World Health Organization Disability Schedule
The WHO-DAS 2.0 measures disability which is due to physical and mental health conditions. The WHO-DAS 2.0 is a 40 item measure that assesses 6 life tasks. The composite score will be used as the dependent variable. The items of the WHO-DAS have a factor loading on composite score of 0.82 to 0.98. The WHO-DAS was the primary outcome in our previous trial of problem-solving treatment and captures all over health disability. Scores range from 0-100 with higher scores equaling greater disability.

Secondary Outcome Measures

Brief Pain Inventory - Interference Scale
The 7 item scale measures pain interference on mood, physical activity, social activity and other life activities. A one-point change is clinically significant. Scores range from 0-10 with higher scores equaling greater pain interference.
Patient Health Questionnaire Somatic Symptom Scale - 15
The PHQ-15 captures somatic symptoms. The PHQ-15 was validated on a sample of 6,000 and found to be reliable, valid and responsive to change. Scores range from 0-30 and higher scores are greater symptom severity.
Patient Activation Measure
The PAM is a 13 item self-report measure of the patient's active engagement in self-management their health. The PAM is reliable and valid. Scores range from 0-100 with higher scores indicating greater activation.
Satisfaction: Patient Satisfaction Questionnaire
The PSQ-III is a 50-item self-report measure with 7 subscales reliability with ranges from .77-.89. The investigators will use the composite score. Score range from 0-100 with higher scores indicating greater satisfaction.
Roland Morris Disability Scale
Pain disability will be assessed with the RMDS a 24 item scale of disability from pain. The RMDS is a core outcome measure for patients with chronic pain. A change of 2-3 points is considered clinically significant. Pain is present in 99% of GWVs with GWI and previous collaborative care trials in the VA have used this measure. Scores range from 0-24 with higher scores = greater disability.
World Health Organization Disability Schedule
The WHO-DAS 2.0 measures disability which is due to physical and mental health conditions. The WHO-DAS 2.0 is a 40 item measure that assesses 6 life tasks. The composite score will be used as the dependent variable. The items of the WHO-DAS have a factor loading on composite score of 0.82 to 0.98. The WHO-DAS was the primary outcome in our previous trial of problem-solving treatment and captures all over health disability. Scores range from 0-100 with higher scores equaling greater disability.
Brief Pain Inventory - Interference Scale
The 7 item scale measures pain interference on mood, physical activity, social activity and other life activities. A one-point change is clinically significant. Scores range from 0-10 with higher scores equaling greater pain interference.
Patient Health Questionnaire Somatic Symptom Scale - 15
The PHQ-15 captures somatic symptoms. The PHQ-15 was validated on a sample of 6,000 and found to be reliable, valid and responsive to change. Scores range from 0-30 and higher scores are greater symptom severity.
Patient Activation Measure
The PAM is a 13 item self-report measure of the patient's active engagement in self-management their health. The PAM is reliable and valid. Scores range from 0-100 with higher scores indicating greater activation.
Satisfaction: Patient Satisfaction Questionnaire
The PSQ-III is a 50-item self-report measure with 7 subscales reliability with ranges from .77-.89. The investigators will use the composite score. Score range from 0-100 with higher scores indicating greater satisfaction.

Full Information

First Posted
May 20, 2020
Last Updated
December 21, 2022
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT04403295
Brief Title
Collaborative Specialty Care for Gulf War Illness
Official Title
Collaborative Specialty Care for Gulf War Illness
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 24, 2020 (Actual)
Primary Completion Date
March 28, 2025 (Anticipated)
Study Completion Date
May 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Gulf War Veterans (GWVs) with Gulf War Illness (GWI) do not receive the care they should in the Veterans Affairs (VA). The investigators' data show 70% of GWVs with Gulf War Illness (GWI) do not receive treatment recommendations for their GWI and 78% are NOT very satisfied with their care. The quality of care GWVs receive must improve. VA and DoD have invested hundreds of millions of dollars to develop new treatments for GWVs, without effective delivery methods GWVs will not benefit. This study will be the first study to examine the best model of care to deliver treatments to GWVs with GWI. Determining the best model of care to translate research into practice is a key goal of the VA Gulf War Strategic Plan and a specific aim of this Request for Applications.
Detailed Description
There is a quality chasm between the care Gulf War Veterans (GWVs) should receive and the care they do receive. The investigators' data show 70% of GWVs with Gulf War Illness (GWI) do not receive treatment recommendations for their GWI and 78% are NOT very satisfied with their care. Reducing this quality chasm is essential. The VA and DoD have invested hundreds of millions of dollars to develop new treatments, including the second largest clinical trial for GWVs which is finding health coaching and problem-solving treatment both reduce the disability of GWI. Without effective models of healthcare to implement these treatments, GWVs will not benefit. In the current model of care, GWVs receive care locally through VA's primary care patient aligned care teams (PACTs). The VA War Related Illness and Injury Study Center (WRIISC) supports the current model of care by increasing local knowledge of the skills and treatments needed to manage GWI through national education efforts and electronic consultation (e-consultation) on difficult cases. The WRIISC and other stakeholders are currently questioning whether improving local knowledge of skills and treatments for GWI is enough to address the quality chasm, or if GWI is too complex to be treated in primary care without additional support from specialists in GWI. A potentially useful model of care for GWI is collaborative specialty care where specialists work with PACTs to synergistically treat patients. The local PACT is the lead of the team with the specialist providing some direct care to the patient (through tele-health) and also consulting with the PACT about other aspects of care. Collaborative specialty care is effective for other complex conditions (e.g., depression) with over 40 studies documenting its efficacy. The goal of this proposal is to conduct a hybrid type 1 randomized effectiveness/implementation trial for GWVs with GWI (n=220). The primary aim is to determine the effectiveness of tele-CSC as compared to e-consultation. In tele-CSC, the investigators' specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the PACT make monthly optimization of analgesics. In e-consultation the specialty provider team will make a onetime recommendation to the PACT that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization. The secondary aim is to understand implementation outcomes. This information will be used to guide a future randomized (by VISN) multi-site implementation study. Throughout, an advisory committee of operations partners will be convened to ensure that the results of the study are able to directly and immediately improve care. Determining the best model of care to translate research into practice for GWVs with GWI is a key goal of the VA Gulf War Strategic Plan and a specific aim of this Request for Applications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gulf War Illness
Keywords
Veteran, Gulf War Illness, implementation, Chronic Pain, health coaching, problem-solving

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
In collaborative specialty care the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics
Masking
InvestigatorOutcomes Assessor
Masking Description
The study coordinator conducting the randomization and study providers will not be blinded. Other staff and investigators (including the Principal Investigator) will be blind to study assignment.
Allocation
Randomized
Enrollment
220 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
collaborative specialty care
Arm Type
Experimental
Arm Description
In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
Arm Title
e-consultation
Arm Type
Active Comparator
Arm Description
In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
Intervention Type
Behavioral
Intervention Name(s)
Collaborative Specialty Care
Intervention Description
In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
Intervention Type
Behavioral
Intervention Name(s)
e-consultation
Intervention Description
In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
Primary Outcome Measure Information:
Title
Roland Morris Disability Scale
Description
Pain disability will be assessed with the RMDS a 24 item scale of disability from pain. The RMDS is a core outcome measure for patients with chronic pain. A change of 2-3 points is considered clinically significant. Pain is present in 99% of GWVs with GWI and previous collaborative care trials in the VA have used this measure. Scores range from 0-24 with higher scores = greater disability.
Time Frame
6 months
Title
World Health Organization Disability Schedule
Description
The WHO-DAS 2.0 measures disability which is due to physical and mental health conditions. The WHO-DAS 2.0 is a 40 item measure that assesses 6 life tasks. The composite score will be used as the dependent variable. The items of the WHO-DAS have a factor loading on composite score of 0.82 to 0.98. The WHO-DAS was the primary outcome in our previous trial of problem-solving treatment and captures all over health disability. Scores range from 0-100 with higher scores equaling greater disability.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Brief Pain Inventory - Interference Scale
Description
The 7 item scale measures pain interference on mood, physical activity, social activity and other life activities. A one-point change is clinically significant. Scores range from 0-10 with higher scores equaling greater pain interference.
Time Frame
6 months
Title
Patient Health Questionnaire Somatic Symptom Scale - 15
Description
The PHQ-15 captures somatic symptoms. The PHQ-15 was validated on a sample of 6,000 and found to be reliable, valid and responsive to change. Scores range from 0-30 and higher scores are greater symptom severity.
Time Frame
6 months
Title
Patient Activation Measure
Description
The PAM is a 13 item self-report measure of the patient's active engagement in self-management their health. The PAM is reliable and valid. Scores range from 0-100 with higher scores indicating greater activation.
Time Frame
6 months
Title
Satisfaction: Patient Satisfaction Questionnaire
Description
The PSQ-III is a 50-item self-report measure with 7 subscales reliability with ranges from .77-.89. The investigators will use the composite score. Score range from 0-100 with higher scores indicating greater satisfaction.
Time Frame
6 month
Title
Roland Morris Disability Scale
Description
Pain disability will be assessed with the RMDS a 24 item scale of disability from pain. The RMDS is a core outcome measure for patients with chronic pain. A change of 2-3 points is considered clinically significant. Pain is present in 99% of GWVs with GWI and previous collaborative care trials in the VA have used this measure. Scores range from 0-24 with higher scores = greater disability.
Time Frame
9 month
Title
World Health Organization Disability Schedule
Description
The WHO-DAS 2.0 measures disability which is due to physical and mental health conditions. The WHO-DAS 2.0 is a 40 item measure that assesses 6 life tasks. The composite score will be used as the dependent variable. The items of the WHO-DAS have a factor loading on composite score of 0.82 to 0.98. The WHO-DAS was the primary outcome in our previous trial of problem-solving treatment and captures all over health disability. Scores range from 0-100 with higher scores equaling greater disability.
Time Frame
9 month
Title
Brief Pain Inventory - Interference Scale
Description
The 7 item scale measures pain interference on mood, physical activity, social activity and other life activities. A one-point change is clinically significant. Scores range from 0-10 with higher scores equaling greater pain interference.
Time Frame
9 month
Title
Patient Health Questionnaire Somatic Symptom Scale - 15
Description
The PHQ-15 captures somatic symptoms. The PHQ-15 was validated on a sample of 6,000 and found to be reliable, valid and responsive to change. Scores range from 0-30 and higher scores are greater symptom severity.
Time Frame
9 month
Title
Patient Activation Measure
Description
The PAM is a 13 item self-report measure of the patient's active engagement in self-management their health. The PAM is reliable and valid. Scores range from 0-100 with higher scores indicating greater activation.
Time Frame
9 month
Title
Satisfaction: Patient Satisfaction Questionnaire
Description
The PSQ-III is a 50-item self-report measure with 7 subscales reliability with ranges from .77-.89. The investigators will use the composite score. Score range from 0-100 with higher scores indicating greater satisfaction.
Time Frame
9 month

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: deployed to Operation Desert Shield/Storm meets Kansas City (Steele) definition of GWI (which excludes conditions that may account for GWI) rates their activity limitations from pain at least 3 on a 0 to 10 point scale has a VA primary care provider Exclusion Criteria: suicidal intent previous evaluation at the WRIISC or participated in our clinical trial for GWVs with GWI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lisa M McAndrew, PhD
Phone
(862) 400-3317
Email
Lisa.Mcandrew@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Nicole Whittaker, MSW
Phone
(973) 676-1000
Ext
201167
Email
nicole.whittaker2@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Marie McAndrew, PhD
Organizational Affiliation
East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Justeen K Hyde, PhD
Organizational Affiliation
VA Bedford HealthCare System, Bedford, MA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Scott E. Sherman, MD MPH
Organizational Affiliation
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
Official's Role
Principal Investigator
Facility Information:
Facility Name
East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ
City
East Orange
State/Province
New Jersey
ZIP/Postal Code
07018
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carmelen B Chiusano, MPA
Phone
(973) 676-1000
Ext
2220
Email
carmelen.chiusano@va.gov
First Name & Middle Initial & Last Name & Degree
Kevin D Beck, PhD
Phone
(973) 676-1000
Email
Kevin.Beck@va.gov
First Name & Middle Initial & Last Name & Degree
Lisa Marie McAndrew, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Collaborative Specialty Care for Gulf War Illness

We'll reach out to this number within 24 hrs